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Osteoporotic-associated vertebral compression fractures are a major public health concern, dwarﬁng even hip fractures in
incidence in the United States. These fractures carry a signiﬁcant morbidity and mortality burden and also represent a major
growing source of consumption of scarce heath resources. Percutaneous vertebroplasty remains a commonly used and safe
technique for the symptomatic treatment of vertebral compression fractures, both osteoporotic- and neoplastic-induced. By
carefully selecting appropriate patients who are referred promptly, vertebroplasty can provide signiﬁcant and durable pain relief
over traditional conservative therapy. Recent controversies surrounding the evidence for vertebroplasty in osteoporotic-associated
vertebral compression fractures are reviewed. A comprehensive step-by-step practical guide to performing vertebroplasty is then
described. A brief description of patient selection, workup, as well as complications is also provided.
1.Introduction
Two related interventional procedures are performed for
the treatment of painful vertebral compression fractures
(VCF), percutaneous vertebroplasty (PV), and kyphoplasty.
BothinvolvetheﬂuoroscopicallyorCT-guidedpercutaneous
placement of wide-bored cannulae into the fractured ver-
tebral body which is subsequently cemented with synthetic
bone cement, typically polymethylmethacrylate (PMMA).
PV was ﬁrst described for the treatment of an aggressive
haemangioma of C2 in 1987 [1, 2], but in subsequent years
hasbeenperformedmainlyforthesymptomatictreatmentof
painful osteoporotic-induced VCF. The palliative treatment
of tumour-induced VCF (typically myeloma or metastatic
disease) remains an important further indication for PV.
VCF is a major public health concern, with an estimated
1.4 million patients presenting with such a fracture each
year [3]. The incidence of VCF in the US alone is estimated
to be 750,000 [4], a ﬁgure that makes VCF more common
thanosteoporotic-relatedhipfractures.Themajorityofthese
vertebral fractures are secondary to osteoporosis. Gradual
pain resolution following these fractures is the expected
natural history, but pain can persist and or resolve slowly
[5]. Pain in these patients is also frequently refractory to
conservative therapy. VCFs can be complicated by defor-
mity, loss of stature, impairment of pulmonary function
and the attendant risks of poor mobility/immobilisation
in the elderly, such as venous thrombo-embolism [6–8].
Immobilisationisalsoassociatedwithincreasedbonedensity
loss and enduring diﬃculty with activities of daily living [9].
An increase in mortality after VCF has been noted. One large
prospective cohort study of elderly patients with low-trauma
osteoporotic VCFs calculated an increased standardized
mortality ratio for women of 1.82 (95% CI 1.52–2.17) and
for men of 2.12 (95% CI 1.66–2.72) [10].
Traditional treatment of uncomplicated VCF consists of
analgesia, bracing, and rehabilitation. Pain often necessitates
bed rest or other restrictions on mobility. Open reduction
and internal ﬁxation is theoretically possible, but rarely
performed due to poor bone stock and multiple underlying2 Radiology Research and Practice
co-morbidities. PV oﬀers a less invasive therapeutic option
for generally elderly patients with multiple comorbidities
which allows for early immobilisation.
2.EvidenceandControversies
Prior to 2009, evidence for the eﬀectiveness of PV in osteo-
porotic VCF was based on anecdotal experience, multiple
prospective and retrospective case series, and prospective
comparative cohort studies [11]. Multiple observational
studies had shown almost uniformly excellent results with
PV, withmoderated tomarked painreliefexperiencedby75–
95% of patients [12–14]. Similar results in the treatment of
metastatic fractures have also been reported [15]. However,
a bias towards overestimation of treatment beneﬁts is
possible when relying on this form of evidence [16, 17].
Well-designed, randomised, prospective trials comparing PV
versus conservative therapy were lacking. In 2009, NEJM
published the results of the ﬁrst two randomised blinded
trials comparing PV with a sham intervention, namely,
local anaesthetic inﬁltration of skin, subcutaneous and
periosteum [18, 19].
Buchbinder et al. [18] enrolled and randomised 78
patients with one or two painful osteoporotic vertebral
fractures (as deﬁned on imaging, predominately MRI) to
either PV or a sham procedure, with followup reported up
to six months. Kallmes et al. [19] enrolled and randomised
131 patients with one to three fractures to PV or a similar
sham procedure; followup was to three months. Both
trials reported no statistically signiﬁcant beneﬁt of PV over
placebo.
The NEJM trials have been criticised on several fronts,
with Buchbinderin particularstrongly defendingthevalidity
ofthetrials inensuingcorrespondence[20,21].Kallmesetal.
[19] allowed cross-over between the two arms at one month.
Forthosereceivingtheshamprocedure,42%optedtoreceive
PV at three months, compared with 12% for the other
arm. This higher rate of cross-over could be interpreted as
reﬂecting dissatisfaction with the sham procedure compared
with PV, or possibly ﬂaws in the blinding of the sham
procedure such that patients were able to “guess” their
intervention.
Mathis [22] and Munk et al. [23]c r i t i c i s e dt h el o w
patient enrolment number compared with length of the
enrolmentperiod.Conceivably,patientswiththemostsevere
pain would be less likely to agree to undergo randomisation,
and the studied population would therefore exclude those
patients with the most severe pain. These authors also point
outthatKallmeswasclosetoprovinga“clinicallymeaningful
improvement in pain for PV compared to sham therapy”
with a P value of .06. If the Kallmes trial had enrolled
19 more participants who experienced similar results, P
would have been <.05 and thus regarded as statistically
signiﬁcant. Mathis concluded that Kallmes therefore did
not enrol enough patients to disprove the eﬀectiveness of
PV. The number of patients enrolled in Buchbinder was
also insuﬃcient to power a subgroup analysis to assess PV
eﬀectiveness in those with fractures less than six weeks
old [24]. The NEJM trials have also been criticised on the
basis of the proportion of eligible patients who declined
enrolment, 70% for Kallmes and 64% for Buchbinder. Bono
et al. [25] suggested this raised the spectre of selection bias.
However, these ﬁgures are not remarkable when compared
with previous experience in blinded randomised controlled
trials.
The expected natural history of VCF is ofgradual healing
and pain relief [26, 27]. Some evidence from observational
studies of PV have shown decreased pain relief and less
improvement in mobility in fractures >12 months when
treated with PV [28]. Based on the patient selection criteria
of both NEJM studies, patients with painful fractures up to
one year of age were included in the trials. Most patients
had pain of >3 months duration. This would have inevitably
resulted in the enrolment of patients with delayed union and
non union, altering the homogeneity of the disease process
studied. The averagereduction in pain as assessed on a visual
analogue scale (VAS) was smaller in the active arms of both
trials than would have been expected from prior observa-
tional studies, raising doubt about the ability to extrapolate
these results to patients with severe pain post-VCF who have
failed conservative treatment. Bono et al. also criticised the
design of the sham procedure, labelling it an alternative
intervention (the injection of long acting local anaesthetic
onto periosteum) rather than a true sham procedure. It is
diﬃcult to imagine, however, how participants in the NEJM
could have been truly blinded without recourse to such a
procedure. Some authors, including the current authors,
advocate ﬂuoroscopic-guided palpation and percussion of
PV candidates, in an attempt to correlate imaging ﬁndings
withsymptoms.Thiswasnotperformedineitherstudy.Both
trials also did not examine the role of PV in nonosteoporotic
vertebral fractures, orexamine therole ofPV inthe inpatient
setting.
More recently, the results of VERTOS II [29]h a v e
become available. This multicenter study was randomised,
but participants, physicians and outcome assessors were not
blinded. Over 200 patients with a VCF and pain of less than
6 weeks duration were randomised to conservativetreatment
orPV.Noshamprocedurewasperformed.Atonemonthand
one year, a statistically signiﬁcant reduction in pain in thePV
arm was evident. Alvarez et al. [11] concludedthat PV is safe
and able to be performed at an acceptable cost. Furthermore
the pain relief following PV is immediate, lasts for at least a
year, and is signiﬁcantly greater than conservative treatment.
Rousing et al. [30] also recently reported 12-month
followup from an open-label, randomised study (n = 50,
fracture age <8 weeks) comparing PV with conservative
management.Immediateandsigniﬁcantpainrelieffollowing
PV was evident. At one-month following discharge, the
PV arm had a statistically signiﬁcantly reduction in pain
compared with the conservative therapy arm. However, no
diﬀerence in pain scores was found between the groups at
3 and 12 months. These authors suggest that the role of
PV may therefore be as a short-term invasive method of
pain control in those who fail conservative treatment or for
those whom conservative treatment and the accompanying
immobilisation carry serious risks.Radiology Research and Practice 3
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Figure 1:Painfulhaemangiomaofright-handaspect ofT8(arrowed) ina56-year-old mantreated withunipedicular vertebroplasty. Sagittal
(a) and axial (b) TSE T2-weighted images. (c): Vertebroplasty spot ﬂuoroscopy image, AP projection. Postprocedure, the patient reported
complete resolution of pain.
3.ConclusionsonAvailable EvidenceforPV
I tc a nb ec o n c l u d e df r o mt h ea v a i l a b l el i t e r a t u r et h a t
long-term eﬀectiveness and complication data from PV is
currently lacking. Performing a true blinded randomised-
controlled trial between conservative therapy and PV is im-
possible. Despite the seemingly conﬂicting available data, it
is the authors’ opinion that there is some evidence available
that in the acute to subacute period, in those who are failing
conservativetreatmentoratareatincreasedriskfromimmo-
bilisation, PV can provide good pain relief compared with
conservative treatment, though as yet no durable long-term
beneﬁt has been demonstrated. When patients are carefully
screened by history, examination, and imaging prior to the
procedure, it is the authors’ opinions that a group highly
likely to signiﬁcantly beneﬁt from PV can routinely be iden-
tiﬁed and then oﬀered PV. PV remains an important inter-
vention for the treatment of intractable pain associated with
neoplasm-inducedVCF(Figure 1),andforthosehospitalised
due to severe pain following osteoporotic-induced VCF.
4. Performing Percutaneous Vertebroplasty
4.1. Patient Selection. Ideally, patients with painful VCF who
are failing conservative treatment should be referred for
PV as early as practicable once it has become clear that
conservative measures are failing, or in cases of severe pain
requiring hospitalisation. Patients with pain of greater than
three months duration are less likely to beneﬁt from PV
[29].
There are few absolute contraindications to PV. Coag-
ulation proﬁle must be normal or near normal, and anti-
coagulants must be ceased prior to the procedure. PV is
contraindicated in those with severe cardiac or respiratory
failure precluding safe conscious sedation or general anaes-
thesia. These patients are considered high risk for clinically
signiﬁcant procedure-related fat embolism [31]. Infection
or fever is also an absolute contraindication. Severe loss of
vertebral body height is a relative contraindication, but good
results can often be obtained in even severely compressed
vertebrae [32].4 Radiology Research and Practice
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Figure 2:SagittalTSET2-weighted (a)andsagittalSTIR (b)ofthethoracolumbarspineina56-year-old manreferred forPVforsevereback
pain followingafall.VCFs are noted atT8 (whitedashed arrow)andT12(continuous white arrow).There isprominentSTIR hyperintensity
atT12withoutsigniﬁcantmarrowedema atT8.The patientwassymptomaticoverT12onpalpation.Thislevelwascemented withcomplete
resolution of symptoms.
Formal prevertebroplastyassessment is performed by the
interventionist one to two weeks before the procedure is
scheduled. At this time, all of the imaging is reviewed. It is
vital to ensure that a recent MRI dating from the time of
symptom onset is available to assess marrow edema in the
target levels. PV is contraindicated if bone marrow edema
is absent on STIR (short-tau inversion recovery) images
(Figure 2). If MRI is contraindicated or unavailable, imaging
assessment can be performed with a combination of CT and
scintigraphic bone scan. CT may also be useful for assessing
pediclebonestockandtheintegrity oftheposteriorvertebral
body cortex in selected patients, particularly in patients with
malignant VCF. Severe loss of bone stock of the pedicle and
posterior vertebral body cortex is a relative contraindication
to PV due to increased risk of symptomatic cement leak.
A comprehensive history is obtained and a thorough
examination is performed. The examination is performed,
in part, in the ﬂuoroscopic suite with the patient prone.
Usefulclinicalinformationcanbeobtainedpriortothisstage
by observing the pain induced by patient mobilising and
climbingontotheﬂuoroscopytable.Itisimportanttocareful
correlate the region of marrow edema on cross-sectional
imaging with the ﬂuoroscopic image of the vertebra. The
patientis then palpated and or gentlypercussed in the region
offractureinan attempttocorrelatesymptoms with imaging
ﬁndings. If there is a clear disparity between the imaging and
the examination ﬁndings, PV is contraindicated. Signs and
symptoms of concurrentfacet or sacroiliacjointdysfunction,
radiculopathy, or sacral insuﬃciency fracturing should be
considered a relative contraindication to PV and prompt
careful reassessment of the patient’s symptoms.
An assessment of the likely ﬂuoroscopic approach to PV
is made to ensure the procedure is technically feasible. Severe
kyphosis and scoliosis are a relative contraindication. Poor
pedicle visualisation and or aberrant anatomy may require
CT-guided placement of bone cannulae. If the patient is
unable to lie prone, general anaesthesia may be indicated. If
t h ep r o c e d u r ei st e c h n i c a l l yf e asible and the imaging ﬁndings
correlate with the examination ﬁndings, the patient is then
educated about the procedure and possible complications,
and informed consent is obtained.
4.2.Procedure. PVentailsthepercutaneousinjectionofbone
cement, typically PMMA, into the collapsed vertebral body.
In our institution, PV is generally performed under general
anaesthesia, although the procedure can be safely performed
under conscious sedation. After prone positioning, the X-
ray tube and image-intensiﬁer is centered over the relevant
vertebral body such that the superior and inferior endplates
are aligned/not obliqued and the spinous process is midline.
The pedicle to be cannulated is then centred in the vertebral
body image via cephalo-caudal tube angulation. Right and
left anterior oblique tube positioning is performed to
visualise the relevant pedicle “en-face.” If biplane is available,
the true lateral projection of the vertebral body is obtained
by ensuring that the posterior vertebral cortex is visualised
in proﬁle without obliquity, the left and right ribs at the
target level (if visible) completely overlap each other andRadiology Research and Practice 5
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Figure 3: Spot ﬂuoroscopic images from two separate patients obtained during PV. (a) demonstrates left bone cannula insitu. The right
pedicle has been cannulated, and is advanced in the AP plane staying clear of the pedicle medial cortical margin. Arrow indicates the
medial pedicle cortex. (b) Lateral projection demonstrates tip of needle anterior to posterior vertebral cortex (dashed white line). Once
this landmark is reached, the cannula can be safely advanced to 1cm posterior to the anterior vertebral cortex under lateral projection
ﬂuoroscopic guidance. Cementing is also performed in this projection.
the target vertebral body is centered in the image. PV can be
safely performed without accessto biplane ﬂuoroscopybutis
signiﬁcantly more time consuming.
With aseptic technique and following local anaesthesia,
an 11G or 13G bone needle is inserted down onto the per-
iosteum overlying the pedicle, aiming for the lateral cortical
margin of the pedicle at the 10:00 position on the left and
the 2:00 position on the right. A transpedicular approach
is the technique of choice. This approach ensures that risk
of damage to adjacent structures is minimised, is easily
learnt,andconvenientlypositions thecannulatipatmaximal
distance from bone entry for cement injection, helping to
minimise leaks. Occasionally, a parapedicular approach may
be necessary due to diﬃcult/distorted anatomy. Cannula ad-
vancement is then performed. Typically, the periosteum is
breached and the cannula advanced with hand pressure and
screwing. Soft osteoporotic bone means that a soft bone
mallet is only occasionally needed for cannula advancement.
An attempt to stay initially lateral to the midline of the
pedicleontheobliqueAPprojectionis madetominimise the
chances of breaching the medial cortex of the pedicle, and
thus entering the spinal canal, during cannula positioning
(Figure 3(a)). After complete cannula engagement of bone,
the true lateral projection is checked for cannula trajectory
in the cephalo-caudal plane. Once the needle is anterior to
the posterior margin of the vertebral body on the lateral
projection, the pedicle has been successfully traversed and
further needle progression can be monitored via the lateral
projection (Figure 3(b)). Prior to this landmark, cannula
progressionshouldonlybeperformed intheobliqueAPpro-
jection, staying clear of the medial pedicle cortical margin.
The tip of the cannula is advanced to a point approx-
imately 1cm posterior to the anterior vertebral body as
assessed laterally. Because the vertebral body is not rectan-
gular but rather curved, leaving a safe gap between these two
pointsisneededtoensuretheanteriorcortexisnotbreached.
The contralateral pedicle is cannulated in a similar fashion.
Bilateral cannulation is favoured due to increased chance of
adequate and safe cement injection. If there is doubt about
the diagnosis, bone biopsy is performed at this stage.
The PMMA cement is prepared by mixing polymer pow-
der with liquid monomer. Mixing of the powder and liquid
leads to exothermic polymerisation and then progressively
thickening of the paste, which subsequently hardens. Once
the cementhas a toothpaste-likeconsistency, injections com-
mence via a 1mL syringe. Continuous screening for cement
extravasation during injection is performed. In particular,
close attention is made to the posterior margin of the verte-
bral body. If cement extends posteriorly within 5mm of this
landmark, injection is ceasedtominimise therisk ofepidural
space cement leak. One needle only at a time is injected. Any
leak or extravasation is an indication to stop injection. Gen-
erally, a small waiting period for the cement to solidify is all
that is required prior to resuming injection. Large leaks may
requiretheprocedurebeabandoned.Attheendoftheproce-
dure when the cannulae are removed, it is advisable to rein-
sert the introducing stylet to push any residual cement into
the needle tract within the bone. A cast of cement deposited
into soft tissues is irritant and can cause signiﬁcant pain.6 Radiology Research and Practice
4.3. Volume of PMMA to Inject. The volume of cement to
be injected at each level for maximal eﬃcacy has not been
accurately determined [33]. In ex vivo studies, Belkoﬀ et
al. [33] demonstrated that vertebral body strength can be
restored with 2mL of cement, whilst restoration of preinjury
stiﬀness required 4–8mL. Regardless of exact measurements,
visual ﬁlling of the body on the AP projection from the inner
margins of the endplates along the lateral 1/3 on each side is
ideal, though this is not always technically feasible (Figure 4)
[31]. The current authors have often found this result to
be achievable with 3–5mL of cement. As pain relief does
not correlate with volume of injected cement [12], visual
inspection of the amount of cement injected to the residual
volume of the compressed vertebra is recommended when
ascertaining total volume of cement to be injected.
4.4. Postprocedure Care. The patient remains supine or sem-
irecumbent for one hour, with monitoring of neurovascular
statusandwoundinspectionevery15and30minutesrespec-
tively. The patient is then gently mobilised. If the status of
the patient is stable, they can be discharged home after two
hours. Occasionally, patients may experience an increase in
pain following PV. This is usually of benign aetiology and
self-limiting [22]. Good pain relief is usually obtained with
oral or parenteral narcotics. Ongoing severe pain, radicular
pain or signs/symptoms of spinal stenosis should prompt
early imaging with CT. Followup for treatment of the pa-
tient’s underlying osteoporosis is mandatory.
4.5. Complications. In general, PV is a safe procedure which
is well tolerated. The overall complication rate in PV for
VCF reported in the literature is low, ranging from 1%
to 10% [13, 34–36]. Complications are considerably more
common in the acute peri-and postoperative period. The
complication rate for malignant tumours is higher than
for benign VCF [36–41], with one review by Murphy and
Deramond [41] estimating the complication rate for OP to
be 1.3% for osteoporotic VCFs, 2.5% for haemangiomata-
associated VCF, and 10% for malignant VCF.
The commonest complication ofPV iscement extravasa-
tion, occurring 26–97% of the time [42]. The vast majority
of leaks are asymptomatic. However, cement leaks can
narrow and/or impinge neural structures, either within
the neural foramina or the epidural space (Figures 5 and
6). [43, 44]. Radiculopathy related to cement leakage is
usually transient and responds well to systemic analgesia
and ortransforaminal nerveblock,although occasional cases
requiring of surgical decompression have been reported [43,
44]. Failure to respond promptly to transforaminal nerve
blockfor radiculopathy or any symptoms referable to central
canal stenosis is an indication for urgent neurosurgical
consultation and decompression.
Systemic cement embolisation is rare, with one study
estimated as much as 5% of patients may undergo cement
pulmonary embolism [45]. These are rarely clinically sig-
niﬁcant [46]. Displaced marrow from the cemented ver-
tebra may also result in fat embolism. Patients with poor
cardiorespiratory function may be at increased risk of this
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Figure 4: Spot AP (a) and lateral (b) ﬂuoroscopicimages following
T8 PV in a 62-year-old man with an osteoporotic VCF. A bi-
pedicular approach was used. There is satisfactory ﬁlling of the
vertebral bodyinthelateralandAPprojectionswithoutevidentleak
(arrows). The patient’s symptoms had resolved on awakening from
the procedure.
complication [46]. As risk of marrow embolisation may be
proportional to volume of displaced marrow during cement
injection, the authors favour performing PV at up to three
levels only at one sitting. Venography prior to cementing
has fallen out of favour [47, 48]a sn oc l i n i c a lb e n e ﬁ t
referable to venography has been demonstrated [28]. OtherRadiology Research and Practice 7
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Figure 5: 86-year-old woman with known multiple myeloma and pathological fracture of T6. During PV, posterior cement leak was noted
soon after injection commenced; the procedure was abandoned. (a): Axial CT demonstrates permeative bone destruction of T6 (black
arrows). Cement has extravasated posteriorly into the epidural space. (b) Sagittal CT demonstrates a thin collection of epidural cement
anterior to the thecal sac (dashed white arrow). The patient remained asymptomatic initially and at followup and decompression was not
required.
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Figure 6: Modern biplane ﬂuoroscopy allows on-table CT to be performed, with multiplanar reformats. Although the images acquired
are susceptible to quantum mottle, the technique is invaluable in PV to quickly assess and conﬁrm cement position and to assess for
complications. Sagittal (a) and coronal (b) reconstructions (Siemens Axiom Artis biplane ﬂuoroscopic unit) are shown in a 78-year-old
man with recent VCF of L1 treated successfully with PV. An old VCF is noted at L2 (white arrow). A trace of lateral cement leak is noted to
the left (dashed black arrow). This was asymptomatic.
complications of PV include bleeding, haematoma, infec-
tion, pneumothorax, pedicle fracture, thecal sac puncture,
and CSF leak. Patients with severely lowered bone mineral
density may experience fractured ribs or sternum whilst
t h ep r o c e d u r ei sp e r f o r m e d[ 49]. Infection is uncommon,
and there is no evidence to support routine antibiotic
impregnation into the cement or intravenous antibiotics at
the time of the procedure [35].
PMMA used during arthroplasty has been associated
with transient hypotension, though a link between PV with8 Radiology Research and Practice
PMMA and cardiovascular eﬀects has not been demon-
strated on retrospective review [50]. The exothermic process
of PMMA polymerisation has led to some concern about
possible associated thermal injury, but in experimental
testing no thermal injury to neurological structures has been
demonstrated [51, 52].
4.6. Risk of Subsequent Fracture at Adjacent Vertebrae. Some
reports in the literature have suggested that PV is associated
with a higher incidence of new VCF at adjacent levels,
possibly reﬂecting a biomechanical consequence of the aug-
mented stiﬀness of the cemented level [53–56]. Recent data
from the VERTOS II trial [57] randomising painful VCFs
to conservative treatment or PV showed the incidence of
new VCF between the two groups was not diﬀerent at 12
months followup, and the only risk factor identiﬁed for new
VCF was the number of baseline VCFs. This adds weight to
the theory that new VCF post-PV are manifestations of the
natural history of osteoporosis rather than reﬂecting a risk
intrinsic to PV.
5.Conclusion
Prompt assessment of PV candidates is integral to success-
fully performing the procedure. The interventionist must
take responsibility for reviewing imaging, taking a thorough
history and examining the patient. Percutaneous vertebro-
plasty is usually technically straight forward and safe as long
as a clear, reproducible, step-by-step approach is employed.
Serious complications are uncommon and pain relief in-
duced is often considerable.
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